PQQ for Memory and Cognitive Function: What the Trials Show, Honestly
Educational summary — not medical advice. This is healthy-adult and one small diagnosed-MCI trial data, not a general dementia- or Alzheimer's-treatment claim, and not a substitute for clinical evaluation of memory concerns. This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
The honest answer
PQQ's strongest, most-replicated evidence pocket — real, but every positive trial is industry-linked. Four separate 20mg/day BioPQQ trials found attention, memory, or cerebral-blood-flow signals in healthy older adults (Itoh/Nakano 2016, Nakano 2016, Tamakoshi 2023), plus a larger trial (Shiojima 2022, n=58) on a different branded ingredient. All are Mitsubishi Gas Chemical or Cepham Inc. affiliated — named on every citation below. One small trial in diagnosed MCI (Baltic 2024) used yet a different PQQ form and is not evidence the healthy-adult findings extend to diagnosed cognitive impairment.
Five trials, read with industry affiliation attached every time
This is the pocket of PQQ evidence that replicates most consistently — which is exactly why the affiliation disclosure matters most here, not least. Every trial below measured an attention, memory, or cerebral-blood-flow outcome; four used the standard 20mg BioPQQ dose in healthy adults, one used a larger dose of a different ingredient, and one used a different form entirely in people with diagnosed mild cognitive impairment.
| Study | Population & design | Dose & duration | Result & affiliation |
|---|---|---|---|
| Itoh/Nakano 2016 PMID 26782228 | RCT, n=41 healthy elderly | 20mg/day BioPQQ, 12wk | Significantly smaller Stroop-interference (attention) decline vs placebo; lower-baseline participants improved on a visual-spatial test; NIRS suggested increased prefrontal blood flow. ⚠️Nakano is a Mitsubishi Gas Chemical employee. |
| Nakano 2016 PMID 27526146 | RCT, n=20 healthy adults 50-70y | 20mg/day BioPQQ, 12wk | Significantly increased right-prefrontal-cortex hemoglobin and oxygen-saturation change (time-resolved NIRS) — a surrogate blood-flow marker, not a cognitive-outcome measure itself. ⚠️Mitsubishi Gas Chemical affiliation; small n=20. |
| Tamakoshi 2023 PMID 36807425 | RCT, ages 20-65, split younger/older groups | 20mg/day PQQ disodium, 12wk | Younger group improved cognitive flexibility/processing speed by wk 8; older group improved complex/verbal memory by wk 12; whole sample improved composite/verbal memory by wk 12. ⚠️Mitsubishi Gas Chemical affiliation; exact per-group n not confirmed from abstract. |
| Shiojima 2022 PMID 34415830 | RCT, n=58 completers (of 64 randomized), healthy Japanese adults ~70-72y | 21.5mg/day mnemoPQQ® (DIFFERENT branded ingredient), 12wk | Significant improvements on Cognitrax composite memory, verbal memory, reaction time, complex attention, cognitive flexibility, executive function, motor speed; DECO and MMSE-J also improved; no adverse events. ⚠️Senior co-author Debasis Bagchi is CSO of Cepham Inc. Largest completer-n trial here, but NOT a BioPQQ replication. |
| Baltic 2024 PMID 38908296 | RCT, n=34 elderly with DIAGNOSED mild cognitive impairment | Dihydrogen-PQQ (Alpha Hope®, different form), 2x/day, 6wk | Serum BDNF rose significantly (p=.01); cerebral oxygenation rose (48.4%→52.8%); ADAS-Cog orientation domain improved (p=.03); brain NAA rose at 7/13 regions. Different PQQ form/dose than BioPQQ trials — never blend as confirming the healthy-adult findings; only diagnosed-MCI trial in this pack, 6 weeks only. |
What "PQQ helps cognition" actually means here
Read precisely, the strongest honest version of this claim is: in a cluster of small, mostly industry-affiliated 12-week trials at the standard 20mg BioPQQ dose, healthy older and middle-aged adults showed improvements on attention, memory, or cerebral-blood-flow measures. That's a real, consistently-replicating signal across four independent research write-ups (though not independent funding) — more consistent than PQQ's cholesterol or exercise findings elsewhere in this evidence base. It does not support "PQQ treats or prevents dementia," "PQQ reverses cognitive decline," or any disease-outcome claim: no trial here enrolled a diagnosed-dementia population except Baltic 2024, which used a different form, a different protocol, and ran only six weeks. It also does not mean the effect is proven independent of who profits from it — five of these six data points (four cognition trials plus the largest trial, Shiojima) are industry-linked, either to Mitsubishi Gas Chemical (BioPQQ's manufacturer) or Cepham Inc. (mnemoPQQ, Shiojima's ingredient). The honest framing is "consistent signal, unreplicated independently," not "proven."
If you're considering PQQ for memory or cognitive function
Go in with the affiliation attached, not just the headline. The dose with the broadest single-dose trial support is 20mg/day (see the dosage guide), matching most retail BioPQQ products (see best PQQ). None of these trials substitute for the interventions with the strongest independent evidence for cognitive health in older adults — aerobic exercise, sleep quality, and cardiovascular risk management chief among them. If a memory concern is persistent, worsening, or affecting daily function, that's a reason to talk to a clinician about a proper cognitive evaluation, not to rely on a supplement with this evidence profile, however consistent the small-trial signal looks.
Frequently asked questions
Does PQQ improve memory and cognitive function?
PQQ's strongest evidence pocket: 4 industry-linked BioPQQ trials plus one larger, differently-branded trial (Shiojima) found attention, memory, or blood-flow signals. Every positive trial has an industry affiliation, disclosed above.
Is PQQ proven to treat dementia or Alzheimer's?
No. The one diagnosed-MCI trial (Baltic 2024) used a different PQQ form over 6 weeks — not evidence for a general dementia-treatment claim, and not the same evidence as the healthy-adult BioPQQ trials.
Is any of this evidence independent of industry?
Not for cognition specifically. All 5 trials in this pocket (4 BioPQQ + Shiojima) have Mitsubishi Gas Chemical or Cepham affiliations. No independent trial has measured PQQ's cognitive effect.
Why does industry affiliation matter this much?
6 of 12 trials in the whole PQQ evidence base are tied to the two companies selling the branded ingredients tested — tighter concentration than NMN's, and independent replication hasn't happened yet.
Related
- PQQ: what it is & who it's for
- PQQ dosage guide — the 20mg standard dose in context
- Best PQQ — BioPQQ-branded vs. generic disodium, ranked
- Does PQQ actually work?
Sources
- Itoh Y, Nakano M, et al. 2016. Adv Exp Med Biol. PMID: 26782228
- Nakano M, et al. 2016. Adv Exp Med Biol. PMID: 27526146
- Tamakoshi M, et al. 2023. Food Funct. PMID: 36807425
- Shiojima Y, Bagchi D, et al. 2022. J Am Nutr Assoc. PMID: 34415830
- Baltic S, et al. 2024. J Nutr Health Aging. PMID: 38908296